

## Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer


### SUPPLEMENTARY MATERIALS

**Supplementary Table 1: Characteristics of tumor-derived A549 cell lines**

Cell line ID	Treatment	Endpoint	Site of cell line
A549R16	None	Control	Primary
A549R1	34 Gy	30 days	Primary
A549R10	34 Gy	10 days	Primary

**Supplementary Table 2: Relative expression of genes involved in adhesion/migration in A549 cells derived from sham-treated tumors or tumors harvested early and late after SABR**

	Relative gene expression (St.Dev.)		
	Sham	Early	Late
PPARGC1A	1.00 (0.40)	17.4 (4.80)	0.90 (0.30)
TSPAN7	1.00 (0.10)	17.1 (1.20)	1.30 (0.20)
FN1	1.00 (0.01)	9.90 (0.60)	1.50 (0.10)
FST	1.00 (0.03)	5.50 (0.20)	0.60 (0.01)
IL-8	1.00 (0.10)	3.40 (0.20)	1.20 (0.10)
BMP6	1.00 (0.10)	3.40 (0.30)	1.20 (0.20)
COL4A5	1.00 (0.10)	3.10 (0.20)	0.80 (0.10)
COL4A6	1.00 (0.02)	2.30 (0.10)	0.60 (0.02)
IL20RB	1.00 (0.10)	0.10 (0.01)	1.60 (0.20)



**Supplementary Figure 1: Relative gene expression of CDH1 (E-cadherin) in A549 cells harvested from sham-treated tumors and tumors harvested early and late after SABR.**